Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
0.235
-0.003 (-1.26%)
At close: Dec 20, 2024, 4:00 PM
0.238
+0.003 (1.28%)
After-hours: Dec 20, 2024, 7:59 PM EST
Cellectar Biosciences Employees
Cellectar Biosciences had 20 employees as of December 31, 2023. The number of employees increased by 5 or 33.33% compared to the previous year.
Employees
20
Change (1Y)
5
Growth (1Y)
33.33%
Revenue / Employee
n/a
Profits / Employee
-$2,505,360
Market Cap
9.70M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Eyenovia | 57 |
Applied DNA Sciences | 55 |
Aptose Biosciences | 36 |
Kiora Pharmaceuticals | 12 |
SeaStar Medical Holding | 12 |
BioRestorative Therapies | 11 |
Can-Fite BioPharma | 8 |
Indaptus Therapeutics | 7 |
CLRB News
- 10 days ago - Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Benzinga
- 11 days ago - Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring - GlobeNewsWire
- 4 weeks ago - NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) - Business Wire
- 4 weeks ago - Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - GlobeNewsWire
- 5 weeks ago - Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 - GlobeNewsWire
- 5 weeks ago - Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - GlobeNewsWire
- 5 weeks ago - Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 - GlobeNewsWire